ECSP17069696A - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- ECSP17069696A ECSP17069696A ECIEPI201769696A ECPI201769696A ECSP17069696A EC SP17069696 A ECSP17069696 A EC SP17069696A EC IEPI201769696 A ECIEPI201769696 A EC IEPI201769696A EC PI201769696 A ECPI201769696 A EC PI201769696A EC SP17069696 A ECSP17069696 A EC SP17069696A
- Authority
- EC
- Ecuador
- Prior art keywords
- novel compounds
- therapy
- processes
- formula
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (I) y sales farmacéuticamente aceptables de estos, en la que X1, X2, X3, Y1, Y2, R1, R2 y R3 son tal como se define en la memoria descriptiva, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504565.1A GB201504565D0 (en) | 2015-03-18 | 2015-03-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17069696A true ECSP17069696A (es) | 2018-02-28 |
Family
ID=53051992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201769696A ECSP17069696A (es) | 2015-03-18 | 2017-10-18 | Compuestos novedosos |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10287286B2 (es) |
| EP (1) | EP3271357B1 (es) |
| JP (1) | JP6726681B2 (es) |
| KR (1) | KR102609431B1 (es) |
| CN (1) | CN107531698B (es) |
| AU (1) | AU2016234209B2 (es) |
| BR (1) | BR112017019653B1 (es) |
| CA (1) | CA2979024C (es) |
| CL (1) | CL2017002354A1 (es) |
| CO (1) | CO2017009353A2 (es) |
| CR (1) | CR20170468A (es) |
| DK (1) | DK3271357T3 (es) |
| DO (1) | DOP2017000209A (es) |
| EA (1) | EA035739B1 (es) |
| EC (1) | ECSP17069696A (es) |
| ES (1) | ES2774052T3 (es) |
| GB (1) | GB201504565D0 (es) |
| GE (2) | GEP20207095B (es) |
| HU (1) | HUE047918T2 (es) |
| IL (1) | IL254277B (es) |
| MX (1) | MX2017011902A (es) |
| MY (1) | MY194873A (es) |
| NZ (1) | NZ735631A (es) |
| PE (1) | PE20180656A1 (es) |
| PH (1) | PH12017501699B1 (es) |
| PT (1) | PT3271357T (es) |
| SG (1) | SG11201707280VA (es) |
| TN (1) | TN2017000384A1 (es) |
| UA (1) | UA123668C2 (es) |
| WO (1) | WO2016148306A1 (es) |
| ZA (1) | ZA201706612B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383747B (es) | 2016-02-24 | 2025-03-14 | Pfizer | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak) |
| WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
| DK3808747T3 (da) * | 2018-09-13 | 2025-02-03 | Kissei Pharmaceutical | Imidazopyridinon-forbindelse |
| AU2020368368B2 (en) * | 2019-10-14 | 2026-03-19 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
| CN110950806A (zh) * | 2019-11-14 | 2020-04-03 | 安庆博曼生物技术有限公司 | 四乙基氯化铵催化嘧啶环羟基氯代制备方法 |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| AR121626A1 (es) | 2020-03-20 | 2022-06-22 | Akebia Therapeutics Inc | Compuestos inhibidores de phd, composiciones y métodos de uso |
| CN115413277B (zh) * | 2020-04-20 | 2023-08-01 | 深圳市塔吉瑞生物医药有限公司 | 吡嗪取代的烟酰胺的固体形式及其制备和用途 |
| JP7654071B2 (ja) * | 2020-10-20 | 2025-03-31 | アムジエン・インコーポレーテツド | 複素環スピロ化合物及び使用方法 |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| WO2023072240A1 (en) | 2021-10-28 | 2023-05-04 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| JP2025500892A (ja) * | 2021-12-17 | 2025-01-15 | アケビア セラピューティクス インコーポレイテッド | 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法 |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| DK135184A (da) * | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner |
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| NZ523807A (en) | 2000-06-30 | 2004-09-24 | Wyeth Corp | Substituted-triazolopyrimidines as anticancer agents |
| JP2010065026A (ja) | 2008-08-13 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤 |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| US8283465B2 (en) * | 2009-07-17 | 2012-10-09 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent |
| JP2011168582A (ja) | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| JPWO2014030716A1 (ja) | 2012-08-23 | 2016-08-08 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
-
2015
- 2015-03-18 GB GBGB1504565.1A patent/GB201504565D0/en not_active Ceased
-
2016
- 2016-03-17 MX MX2017011902A patent/MX2017011902A/es active IP Right Grant
- 2016-03-17 CN CN201680022416.0A patent/CN107531698B/zh active Active
- 2016-03-17 BR BR112017019653-0A patent/BR112017019653B1/pt active IP Right Grant
- 2016-03-17 GE GEAP201614608A patent/GEP20207095B/en unknown
- 2016-03-17 ES ES16715122T patent/ES2774052T3/es active Active
- 2016-03-17 SG SG11201707280VA patent/SG11201707280VA/en unknown
- 2016-03-17 EP EP16715122.4A patent/EP3271357B1/en active Active
- 2016-03-17 NZ NZ735631A patent/NZ735631A/en unknown
- 2016-03-17 JP JP2017549107A patent/JP6726681B2/ja active Active
- 2016-03-17 CA CA2979024A patent/CA2979024C/en active Active
- 2016-03-17 WO PCT/JP2016/059782 patent/WO2016148306A1/en not_active Ceased
- 2016-03-17 PT PT167151224T patent/PT3271357T/pt unknown
- 2016-03-17 CR CR20170468A patent/CR20170468A/es unknown
- 2016-03-17 HU HUE16715122A patent/HUE047918T2/hu unknown
- 2016-03-17 UA UAA201708877A patent/UA123668C2/uk unknown
- 2016-03-17 PE PE2018000126A patent/PE20180656A1/es unknown
- 2016-03-17 DK DK16715122.4T patent/DK3271357T3/da active
- 2016-03-17 PH PH1/2017/501699A patent/PH12017501699B1/en unknown
- 2016-03-17 KR KR1020177030091A patent/KR102609431B1/ko active Active
- 2016-03-17 EA EA201792057A patent/EA035739B1/ru unknown
- 2016-03-17 AU AU2016234209A patent/AU2016234209B2/en active Active
- 2016-03-17 US US15/558,824 patent/US10287286B2/en active Active
- 2016-03-17 MY MYPI2017703420A patent/MY194873A/en unknown
- 2016-03-17 TN TNP/2017/000384A patent/TN2017000384A1/en unknown
- 2016-03-17 GE GEAP201914608A patent/GEAP201914608A/en unknown
-
2017
- 2017-09-03 IL IL254277A patent/IL254277B/en active IP Right Grant
- 2017-09-14 CO CONC2017/0009353A patent/CO2017009353A2/es unknown
- 2017-09-15 CL CL2017002354A patent/CL2017002354A1/es unknown
- 2017-09-18 DO DO2017000209A patent/DOP2017000209A/es unknown
- 2017-10-02 ZA ZA2017/06612A patent/ZA201706612B/en unknown
- 2017-10-18 EC ECIEPI201769696A patent/ECSP17069696A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170468A (es) | Compuestos novedosos | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| ECSP16074478A (es) | Compuestos novedosos | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| ECSP17039611A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| MX381707B (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| ECSP14013215A (es) | Compuestos novedosos | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| DOP2017000202A (es) | Desacetoxitubulisina h y análogos de esta | |
| MX2018005725A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| ECSP18056196A (es) | Derivados de indano | |
| ECSP17063489A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY36464A (es) | Compuestos de quinazolina |